button bars forest bayes pooled summary circles
 
DCR

es-BC - TNBC - NA - all population breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 -
versus placebo
durvalumab alone vs. placebo 1 -
pembrolizumab alone vs. placebo 1 -
versus placebo plus SoC
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo plus SoC 1 -

es-BC - TNBC - NA - PDL1 positive breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - PDL1 positive

versus placebo plus SoC
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo plus SoC 1 -

mBC - Triple negative (TNBC) - 1st Line (L1) breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1)

mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 -
versus Standard of Care (SoC)
atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) 1 -
atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1 -

mBC - TNBC - L1 - PDL1 positive breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - PDL1 positive

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 2 -
versus Standard of Care (SoC)
atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) 1 -
atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1 -

mBC-Triple negative (TNBC) - 2nd Line (L2) breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2)

mBC - TNBC - L2 - all population breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2) mBC - TNBC - L2 - all population

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 certainty unassessable-37%

mBC - TNBC - L2 - PDL1 positive breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2) mBC - TNBC - L2 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 2 -

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons